Post-approval studies (Phase 4)UnknownNCT03172377
What this trial is testing
Lengthening Adalimumab Dosing Interval in Quiescent Crohn's Disease Patients
Who this might be right for
Crohn Disease in RemissionCrohn Disease
Radboud University Medical Center 174